Marshall Wace’s Novavax NVAX Stock Holding History

Marshall Wace’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$814	–	3559
2026 Q1	$814	Buy	+100	New	+$906	﹤0.01%	3127

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Marshall Wace's NVAX Position: Q2 2026 in Review

Marshall Wace reduced its Novavax (NVAX) stake by 44% in Q2 2026, selling an estimated $4.6M and leaving 652,773 shares worth $6.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Marshall Wace first reported a position in NVAX in Q4 2020 and has held it in 13 quarters since. The position peaked at $9.49M in Q1 2026. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Marshall Wace held 652,773 shares of Novavax worth $6.15M as of Q2 2026.
Marshall Wace sold 513,424 Novavax shares in Q2 2026, an estimated $4.6M.
Novavax made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1266 holding.
Marshall Wace first reported a position in Novavax in Q4 2020 and has held it in 13 quarters since.
Marshall Wace's Novavax position peaked at $9.49M in Q1 2026.
268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.